title: [Slow the pace of renal failure in autosomal dominant polycystic kidney disease: hopes and disappointments].
abstract: Autosomal dominant polycystic kidney disease is the most frequent renal genetic disease. Its main complication is renal failure. Despite a better understanding of the mechanisms leading to cyst development and growth, no specific treatment is available. Inhibition of mTOR pathway was a great hope, unfortunately, two clinical trials failed to show a clinical benefit. Numerous new drugs are in clinical trials or in the pipe-line. We could hope, in the 5 years to the emergence of an efficient treatment to slow the pace of renal failure in ADPKD.
authors.affiliation: Hôpital de la conception, centre de néphrologie et transplantation rénale, 13005 Marseille, France. stephaneb@ap-hm.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Burtey
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics; D002986:Clinical Trials as Topic; D015897:Comorbidity; D000242:Cyclic AMP / Q000378:metabolism; D004252:DNA Mutational Analysis; D015507:Drugs, Investigational / Q000627:therapeutic use; D006580:Genetic Carrier Screening; D006655:Histone Deacetylases / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D007677:Kidney Function Tests; D008687:Metformin / Q000627:therapeutic use; D051379:Mice; D016891:Polycystic Kidney, Autosomal Dominant / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D051381:Rats; D015398:Signal Transduction / Q000235:genetics; D013004:Somatostatin / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D050396:TRPP Cation Channels / Q000235:genetics; D000077602:Tolvaptan; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000242:Cyclic AMP; D015507:Drugs, Investigational; D006655:Histone Deacetylases; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D008687:Metformin; D013004:Somatostatin; D058570:TOR Serine-Threonine Kinases; D050396:TRPP Cation Channels; D000077602:Tolvaptan; D014635:Valproic Acid; C546842:MTOR protein, human